Orbital metastasis is an uncommon clinical entity present in 2%-5% of cancer patients.\[[@ref1][@ref2][@ref3]\] Approximately 25% of orbital metastasis present with an occult primary, that is, before the diagnosis of primary malignancy is established.\[[@ref1][@ref2][@ref3]\] The presenting ophthalmic features include proptosis, diplopia, orbital mass and reduced visual acuity. In males, the prostatic (12%) and lung carcinoma (8%) are common primary sites, whereas in females, the breast carcinoma (53%) tops the list.\[[@ref1][@ref2][@ref3]\]

The orbital metastasis of urinary bladder carcinoma is rare and occurs late in the disease process.\[[@ref4][@ref5][@ref6]\] Additionally, the delayed diagnosis imposes a greater management challenge which is frequently associated with a poorer prognosis.\[[@ref1][@ref7]\] Moreover, the trivial systemic symptoms of the patients often get missed, adding to this perplexing scenario.\[[@ref4][@ref5][@ref6][@ref7]\] This necessitates a detailed clinical history, thorough local and systemic examination with radiological support, specifically in elderly, presenting with acute onset of orbital features.

Our patient was an elderly male with unilateral proptosis of short duration and restriction of ocular movements with a contrast-enhancing anterior orbital mass. The histopathology of the excised mass revealed a tumor of metastatic origin enabling us to diagnose the primary cancer.

Case Report {#sec1-2}
===========

A 60-year-old male patient presented with left eye protrusion, diminution of vision and redness of 2 months duration. It was associated with pain, watering and intermittent double vision since 2 weeks. There was no history of significant weight loss, abdominal pain or swellings over other parts of body. He was chronic smoker, occasional alcoholic and was under treatment for hypertension and coronary artery disease. On ophthalmic examination, the best corrected visual acuity was 6/6 and 6/12 in right and left eyes, respectively. The left eye showed proptosis of 4 mm (Leudde\'s exophthalmometery), widened vertical palpebral fissure and mild inferolateral globe dystopia \[Fig. [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\]. The patient had bilateral upper and left lower eyelid retraction. The palpation revealed a firm, non-tender, localized and immobile mass of 2 × 1.5 cm in the left superomedial orbit. The adduction and elevation of the left eye were limited \[Fig. [1c](#F1){ref-type="fig"} and [d](#F1){ref-type="fig"}\].

![(a) Primary gaze photograph shows bilateral upper eyelid retraction, down and out protrusion of left eye, conjunctival congestion and bilateral temporal flare. (b) Oblique view shows the degree of protrusion and eyelid retraction of left eye. (c) The elevation of the left eye appears limited. (d) The adduction of the left eye appears limited](IJO-67-1377-g001){#F1}

At presentation, a contrast-enhanced computed tomography scan of orbits revealed a well-defined, homogenous mass, abutting left globe with marked contrast enhancement \[[Fig. 2a](#F2){ref-type="fig"}\]. The anterior portion of medial rectus appeared thickened and the optic nerve was not discernible \[[Fig. 2b](#F2){ref-type="fig"}\]. A working diagnosis of orbital lympho-proliferative disease was kept and a left anterior orbitotomy with in-toto mass excision was performed. The excised mass was sent for histopathological examination.

![(a) Axial section of contrast-enhanced CT scan (superior orbit) shows a well-defined mass of 2.3 × 2.7 × 8.0 cm abutting left globe with marked contrast enhancement. (b) Mid-orbit level axial scan shows thickened proximal medial rectus muscle with an intraconal retrobulbar component of mass lesion](IJO-67-1377-g002){#F2}

The slides showed tumor cells arranged in nests and clusters with interconnected trabeculae and intervening fibrovascular tissue \[Fig. [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}\] with morphologic features of an epithelial malignancy. On immunohistochemistry, the cells showed strong expression for cytokeratin 7 \[[Fig. 3c](#F3){ref-type="fig"}\] and diffuse, strong nuclear positivity for GATA 3 \[[Fig. 3d](#F3){ref-type="fig"}\], thereby confirming urinary bladder as the likely primary origin. The cells were negative for prostate specific antigen (PSA) excluding prostate gland as primary \[[Fig. 3e](#F3){ref-type="fig"}\].

![(a) Low magnification demonstrating tumor cells arranged in nest and trabeculae (H and E × 200). (b) Moderately pleomorphic, round to oval cells with moderate cytoplasm (H and E × 400). (c) Diffuse strong positivity for cytokeratin 7 (immunoperoxidase × 400). (d) Diffuse nuclear positivity for GATA 3 (immunoperoxidase × 400). (e). Tumor cells were negative for PSA (immunoperoxidase × 400)](IJO-67-1377-g003){#F3}

A metastatic workup including a chest X-ray, ultrasound abdomen and a positron-emission tomography (PET) scan was subsequently requested. The PET scan showed high metabolic activity and FDG uptake in left orbit, para-aortic lymph nodes, urinary bladder and prostate region, suggestive of metastasis. The oncology opinion revealed a urinary bladder carcinoma. The bilateral eyelid retraction was thought to be part of a paraneoplastic syndrome leading to the thyroid associated ophthalmopathy like effects of antibodies on the orbital receptors.\[[@ref8]\] The patient expired within 6 months of the diagnosis of orbital malignancy.

Discussion {#sec1-3}
==========

The median survival of patients with orbital metastasis is 6-9 months.\[[@ref1][@ref2][@ref7]\] Transitional cell carcinoma (TCC) is a common urinary bladder malignancy of which, 10%-15% are invasive.\[[@ref4][@ref5][@ref6][@ref7]\] Of the invasive TCC, around 50% cause distant metastasis to the common sites such as lymph nodes, lungs, bones and rarely to orbit, via the Batson valveless venous plexus.\[[@ref7][@ref9]\] Urinary bladder adenocarcinoma is the third most common histological variant accounting for 0.5%-2.0% of all urinary bladder carcinomas.\[[@ref10]\] The adenocarcinomas are almost always invasive, have a poorer prognosis and regardless of the treatment modality; the five-year survival rate is 0%-31%.\[[@ref10]\]

To the best of our knowledge based on the review of literature (English language), this is possibly the first case report of urinary bladder adenocarcinoma with orbital metastasis. We have compiled the previous reported cases of orbital metastasis from urinary bladder carcinoma (urothelial origin) \[[Table 1](#T1){ref-type="table"}\]. Of total 17 patients (including our case), 14 (82.4%) were males. The mean age at presentation was 67 years (range 45-78 years) and the time period between the onset of ophthalmic symptoms and detection of primary urinary bladder carcinoma ranged from 3 days to 11 years. However, in six cases, the ophthalmic symptoms appeared prior to or simultaneously with the primary carcinoma.

###### 

Reported cases of orbital metastasis from urinary bladder carcinoma

  Sl. No.   Author/year          Age (years)/gender   Time interval between onset of ophthalmic symptoms and detection of urinary bladder carcinoma   Ophthalmic features                                                                                                       Treatment                                                Period from ophthalmic symptoms to death   Results/final outcome
  --------- -------------------- -------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------ -----------------------
  1         Smiley/1965          75/M                 Orbital lesions appeared simultaneously                                                         Diplopia, proptosis, vision loss                                                                                          Not mentioned                                            Not mentioned                              Not mentioned
  2         Seimiya/1971         55/M                 5 months                                                                                        Left sided swelling, pain (bilateral)                                                                                     Radiotherapy                                             8 months                                   Death
  3         Krauss/1982          64/F                 15 months                                                                                       Diplopia, proptosis, pain                                                                                                 Radiotherapy                                             1 month                                    Death
  4         Prats/1989           58/M                 Orbital lesions appeared simultaneously                                                         Diplopia, proptosis, ptosis, hypoesthesia of trigeminal nerve, vision loss                                                Not mentioned                                            4 months                                   Death
  5         Anguro/1991          61/M                 11 months                                                                                       Diplopia, proptosis                                                                                                       Not mentioned                                            1 month                                    Death
  6         Felip/1991           58/M                 Orbital lesions appeared simultaneously                                                         Diplopia, ptosis, hypoesthesia of trigeminal nerve, vision loss                                                           Radiotherapy                                             3 months                                   Death
  7         Felip/1991           62/M                 3 years                                                                                         Diplopia, proptosis, vision loss                                                                                          Refused for treatment                                    Not mentioned                              Not mentioned
  8         Hugkulstone/ 1994    45/M                 Orbital lesions appeared simultaneously                                                         Diplopia, left conjunctival mass, red eye (bilateral)                                                                     Not mentioned                                            5 months                                   Death
  9         Scott/1995           73/M                 3 years                                                                                         Diplopia, proptosis, pain                                                                                                 Radiotherapy + retrobulbar alcohol injection + steroid   13 days                                    Death
  10        Fynn-Thompson/2003   68/M                 11 years                                                                                        Diplopia, proptosis, vision loss                                                                                          Not mentioned                                            1 month                                    Death
  11        Chua/2004            78/F                 4 years                                                                                         Diplopia, red eye                                                                                                         Radiotherapy + Chemotherapy                              1 month                                    Death
  12        Souza Filho/2004     53/M                 3 weeks                                                                                         Diplopia, proptosis, vision loss                                                                                          Not mentioned                                            1 month                                    Death
  13        Shikishima/ 2006     74/M                 3 years                                                                                         Diplopia, proptosis, red eye, pain, vision loss                                                                           Radiotherapy + Chemotherapy                              7 months                                   Death
  14        Lin/2007             60/M                 8 months                                                                                        Diplopia, blurred vision, proptosis, chemosis of conjunctiva, global extraocular movements restriction                    Chemotherapy                                             Not mentioned                              Not mentioned
  15        Magrath/2014         57/F                 3 days                                                                                          Proptosis, decreased vision, global extraocular movements restriction                                                     Palliative care                                          Not mentioned                              Not mentioned
  16        Genc 2017            67/M                 Orbital lesions appeared simultaneously                                                         Limitation of movements, diminution of vision                                                                             Palliative chemotherapy + radiotherapy                   Not mentioned                              Not mentioned
  17        Current case         60/M                 1 year                                                                                          Decreased vision, proptosis, widened palpebral fissure, restriction in ocular motility, diplopia, palpable orbital mass   Chemotherapy                                             6 months                                   Death

The clinical presentation of orbital metastasis depends on the orbital or periorbital structures involved. The common symptoms include pain, globe protrusion, diplopia, redness and decreased visual acuity all in rapid progress.\[[@ref1][@ref3]\] Diplopia (88.2%) was the most common presenting complaint followed by proptosis (70.6%) and diminution of vision or vision loss in 8 (47.1%). The other prominent features were limitation of ocular movements, blepharoptosis and pain while occasionally optic disc edema, exudative retinal detachment, uveitis, choroiditis, secondary glaucoma and widening of palpebral fissure.\[[@ref3]\] Of 17 patients mentioned in [Table 1](#T1){ref-type="table"}, the majority (*n* = 12) died at a mean duration of 3.2 months after the diagnosis of orbital metastasis, and 5 have not clear final status.

A high index of suspicion is critical for an early diagnosis of the orbital metastasis. The above mentioned ophthalmic features, tailored laboratory investigations, appropriate radiology (for extent, dimensions and vascularity) and metastatic workup may provide sufficient diagnostic clues. A PET scan provides sufficient radiological evidence of a metabolically active lesion or tumor with its possible sites of metastasis.

Minimally invasive diagnostic techniques such as ultrasonography guided a fine needle aspiration cytology or an incisional tissue biopsy, from the primary and/or metastatic site, may provide conclusive evidence of the suspected condition. The pathological diagnosis is necessary for initiating anti-cancer treatment in the form of chemotherapy, radiotherapy or immunotherapy.\[[@ref7][@ref9][@ref10]\] The immunohistochemical studies from the metastatic tumor site and its comparison with the primary tumor may be necessary for a definitive diagnosis.\[[@ref6]\] In conclusion, a sudden-onset proptosis with ocular movement restriction should incite a high-index of suspicion for orbital metastasis, especially in elderly.
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